Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab
Nobuharu Tamaki, Toshifumi Tada, Masayuki Kurosaki, Yutaka Yasui, Hironori Ochi, Toshie Mashiba, Azusa Sakamoto, Hiroyuki Marusawa, Ryoichi Narita, Yasushi Uchida, Takehiro Akahane, Masahiko Kondo, Nami Mori, Shintaro Takaki, Keiji Tsuji, Haruhiko Kobashi, Atsunori Kusakabe, Koichiro Furuta, Hirotaka Arai, Michiko Nonogi, Chikara Ogawa, Takashi Sato, Takashi Tamada, Shinichiro Nakamura, Chitomi Hasebe, Kaoru Tsuchiya, Namiki Izumi
Topics & Concepts
MedicineInternal medicineHepatocellular carcinomaAtezolizumabResponse Evaluation Criteria in Solid TumorsHazard ratioConfidence intervalBevacizumabOdds ratioOncologyAlpha-fetoproteinGastroenterologyProgressive diseaseCancerChemotherapyImmunotherapyNivolumabHepatocellular Carcinoma Treatment and PrognosisPancreatic and Hepatic Oncology ResearchCholangiocarcinoma and Gallbladder Cancer Studies